Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5879351 | 0.78 | KIF11 (0.38) | KIF11SLC6A4SLC6A3TSHRSCN5A | |
| SCHEMBL5879396 | 0.75 | SIGMAR1 (0.36) | KIF11TSHRSIGMAR1 | |
| SCHEMBL6990801 | 0.74 | TSHR (0.39) | KIF11SLC6A4SLC6A3TSHRPNMT | |
| SCHEMBL9573655 | 0.67 | TSHR (0.44) | KIF11SLC6A4SLC6A3TSHRSIGMAR1 | |
| SCHEMBL28778794 | 0.66 | TSHR (0.40) | KIF11SLC6A4SLC6A3TSHRPNMT | |
| SCHEMBL26305837 | 0.65 | TSHR (0.45) | KIF11TSHR | |
| SCHEMBL13946948 | 0.64 | TSHR (0.41) | KIF11SLC6A4SLC6A3TSHR | |
| SCHEMBL6986308 | 0.63 | TSHR (0.40) | KIF11SLC6A4SLC6A3TSHR | |
| SCHEMBL11882958 | 0.63 | TSHR (0.40) | KIF11TSHRPNMT | |
| SCHEMBL6950506 | 0.63 | KIF11 (0.39) | KIF11TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7034056-B2 | Aryl and biaryl compounds having MCH modulatory activity | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2006-04-25 | — | — | US | disclosed |
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | SCHERING CORPORATION | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092715-A1 | Aryl and biaryl compounds having MCH modulatory activity | MCHR1, MCHR2, MC3R | KIF11 3324/4885SLC6A4 1047/4885SLC6A3 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.